Donepezil: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
* Major Indication: Alzheimer's Disease<br /> | * Major Indication: Alzheimer's Disease<br /> | ||
* Drug Class: [[Acetylcholinesterase]] Inhibitor | * Drug Class: [[Acetylcholinesterase]] Inhibitor | ||
* Date of FDA Approval ( | * Date of FDA Approval (Patent Expiration): 1996 (2008)<br /> | ||
* 2006 Sales: $800 Million | * 2006 Sales: $800 Million | ||
* Why You Should Care: One of the most effective treatments for teh symptoms of [[Alzheimer's Disease]], although no definitive proof exists as to whether to alters the progression of the disease. | * Why You Should Care: One of the most effective treatments for teh symptoms of [[Alzheimer's Disease]], although no definitive proof exists as to whether to alters the progression of the disease. | ||